AR101256A1 - VACCINE COMPOSITION THAT INCLUDES IPV AND CYCLODEXTRINES - Google Patents

VACCINE COMPOSITION THAT INCLUDES IPV AND CYCLODEXTRINES

Info

Publication number
AR101256A1
AR101256A1 ARP150102293A ARP150102293A AR101256A1 AR 101256 A1 AR101256 A1 AR 101256A1 AR P150102293 A ARP150102293 A AR P150102293A AR P150102293 A ARP150102293 A AR P150102293A AR 101256 A1 AR101256 A1 AR 101256A1
Authority
AR
Argentina
Prior art keywords
cyclodextrin
ipv
composition
antigen
vaccine
Prior art date
Application number
ARP150102293A
Other languages
Spanish (es)
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of AR101256A1 publication Critical patent/AR101256A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Composición inmunogénica que comprende al menos un serotipo del poliovirus inactivado (IPV) y al menos una ciclodextrina o derivado de la misma, especialmente b-ciclodextrina, g-ciclodextrina o 2-hidroxipropil g-ciclodextrina, y antígenos adicionales, dicha composición está protegida contra la pérdida del título IPV inducida por tiomersal. Composición inmunogénica para su uso como una vacuna así como también el uso de una ciclodextrina, o un derivado de la misma para preservar la inmunogenicidad a la IPV en presencia de tiomersal. Método para preparar una composición vacunal y método para inmunizar un huésped contra la poliomielitis. Reivindicación 3: La composición de acuerdo con cualquiera de la reivindicación 1 y 2, en donde dicha composición comprende uno o más antígenos adicionales, preferentemente seleccionados del grupo que comprende toxoide diftérico, toxoide tetánico, antígeno Pertussis, antígeno Neisseria meningitidis, antígeno de superficie de la hepatitis B y antígeno Haemophilus influenzae b (Hib).Immunogenic composition comprising at least one inactivated poliovirus (IPV) serotype and at least one cyclodextrin or derivative thereof, especially b-cyclodextrin, g-cyclodextrin or 2-hydroxypropyl g-cyclodextrin, and additional antigens, said composition is protected against the loss of the IPV titer induced by thiomersal. Immunogenic composition for use as a vaccine as well as the use of a cyclodextrin, or a derivative thereof to preserve IPV immunogenicity in the presence of thiomersal. Method for preparing a vaccine composition and method for immunizing a host against polio. Claim 3: The composition according to any one of claims 1 and 2, wherein said composition comprises one or more additional antigens, preferably selected from the group comprising diphtheria toxoid, tetanus toxoid, Pertussis antigen, Neisseria meningitidis antigen, surface antigen of hepatitis B and Haemophilus influenzae b (Hib) antigen.

ARP150102293A 2014-07-21 2015-07-20 VACCINE COMPOSITION THAT INCLUDES IPV AND CYCLODEXTRINES AR101256A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14306179 2014-07-21

Publications (1)

Publication Number Publication Date
AR101256A1 true AR101256A1 (en) 2016-12-07

Family

ID=51263343

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150102293A AR101256A1 (en) 2014-07-21 2015-07-20 VACCINE COMPOSITION THAT INCLUDES IPV AND CYCLODEXTRINES

Country Status (2)

Country Link
AR (1) AR101256A1 (en)
WO (1) WO2016012385A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160147960A (en) 2014-04-25 2016-12-23 아지노모토 가부시키가이샤 Immunostimulating agent
JP2018536645A (en) 2015-10-28 2018-12-13 味の素株式会社 Immunostimulator
CN112516325B (en) * 2019-09-18 2023-12-08 洛阳赛威生物科技有限公司 Stable foot-and-mouth disease vaccine composition and application thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525349A (en) 1981-12-29 1985-06-25 Societe Anonyme Dite: Institut Merueux Process for the large-scale production of a vaccine against poliomyelitis and the resulting vaccine
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
CZ283910B6 (en) 1992-05-23 1998-07-15 Smithkline Beecham Biologicals (S.A.) Combined inoculation preparation
PL170980B1 (en) 1992-06-25 1997-02-28 Smithkline Beecham Biolog Vaccine
ES2162139T5 (en) 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. VACCINE COMPOSITIONS CONTAINING MONOFOSFORIL-LIPIDO TO 3-O-DISABLED.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
UA56132C2 (en) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine
BRPI9710460B8 (en) 1996-07-02 2021-05-25 Aventis Pasteur multivalent immunogenic composition and vaccine composition
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
FR2763244B1 (en) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc MULTIVALENT VACCINE COMPOSITION WITH MIXED CARRIER
US6835721B2 (en) 1999-02-01 2004-12-28 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof
US8409587B2 (en) * 2002-11-01 2013-04-02 Glaxosmithkline Biologicals S.A. Immunogenic composition
EA016417B1 (en) 2006-09-07 2012-04-30 Глаксосмитклайн Байолоджикалс С.А. Method of making vaccine
WO2012028315A1 (en) 2010-09-02 2012-03-08 Sanofi Pasteur Sa A stabilizer for the preparation of a dry polio injectable vaccine composition

Also Published As

Publication number Publication date
WO2016012385A1 (en) 2016-01-28

Similar Documents

Publication Publication Date Title
UY37811A (en) AN IMMUNOGENIC COMPOSITION THAT HAS IMPROVED STABILITY, POTENTIAL IMMUNOGENICITY AND REDUCED REACTOGENICITY AND PROCESS FOR THE PREPARATION OF THE SAME
MX2023000211A (en) Vaccine compositions having improved stability and immunogenicity.
WO2012093406A3 (en) A combination heptavalent vaccine
NO20090897L (en) Vaccine
TW200719912A (en) Porcine circovirus and helicobacter combination vaccines and methods of use
WO2008112344A3 (en) Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
MY187462A (en) Modified virus-like particles of cmv
AR092896A1 (en) IMMUNOGENIC COMPOSITIONS
WO2015142671A3 (en) Influenza virus vectors and uses therefor
MX2021006342A (en) Influenza virus mutants and uses therefor.
CO6430434A2 (en) NEW COMPOSITIONS OF VACCINES WITH ACCELULAR PERTUSSIS AND MANUFACTURING METHOD OF THE SAME
TW200722101A (en) Novel composition
EP2601969A3 (en) Norovirus vaccine formulations
BR112012033767A2 (en) process for producing a virus of interest, for removing an adventitious agent, and for removing an adventitious agent, virus, and immunogenic composition or vaccine.
MX346245B (en) Fusion protein comprising diphtheria toxin non-toxic mutant crm197 or fragment thereof.
AR101256A1 (en) VACCINE COMPOSITION THAT INCLUDES IPV AND CYCLODEXTRINES
BR112016029513A2 (en) vaccine; process for preparing a vaccine; and method for vaccinating a nonhuman animal
WO2014009971A3 (en) Non-alcoholic vaccine compositions free from animal- origin and process for preparation thereof
CU20190013A7 (en) COMPOSITIONS OF MULTIVALENT VACCINES
CO6430435A2 (en) NEW VACCINES COMBINED WITH COMPLETE CELLS OF PERTUSSIS AND MANUFACTURING METHOD OF THE SAME
MX2018010920A (en) Novel polysaccharide-protein conjugates and process to obtain thereof.
PE20211648A1 (en) COMPOSITION OF COMBINED VACCINE INCLUDING REDUCED DOSES OF INACTIVATED POLIO VIRUS AND METHOD OF PREPARING IT
WO2011074006A3 (en) Vaccine composition
CL2020002876A1 (en) Infectious Bronchitis Vaccine (Divisional Application No. 201803420)
WO2016120596A8 (en) Multi-epitopic construct

Legal Events

Date Code Title Description
FB Suspension of granting procedure